Shareholders, especially long term, have suffered under the current leadership. 

There needs to be dramatic changes especially at the top.

Leading with changes in leadership that result in more shareholder friendly approaches.

Leadership should be paid with shares, buyouts should be considered and the marketing and investor relations team needs to be revamped.

We the shareholder believe in the drug but the leadership has destroyed any aspect of growth in this booming sector of oncology.